Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96EB1

UPID:
ELP4_HUMAN

ALTERNATIVE NAMES:
PAX6 neighbor gene protein

ALTERNATIVE UPACC:
Q96EB1; B4E3W0; E7EPZ6; Q9H4E8; Q9NX11

BACKGROUND:
Elongator complex protein 4 is integral to tRNA modifications, including mcm5U, mcm5s2U, and ncm5U, as part of the elongator complex. These modifications are vital for protein synthesis and cellular function.

THERAPEUTIC SIGNIFICANCE:
Linked to Aniridia 2 through a mutation that affects PAX6 expression, Elongator complex protein 4's involvement in this eye disorder highlights its potential as a target for therapeutic intervention. Understanding its role could lead to breakthroughs in treating Aniridia 2 and improving visual outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.